Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2012 Mar 2.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):556–562. doi: 10.1161/ATVBAHA.111.244608

Critical Review of Mouse Models of Venous Thrombosis

Jose Antionio Diaz 1, Andrea T Obi 1, Daniel D Myers Jr 1, Shirley K Wrobleski 1, Peter K Henke 1, Nigel Mackman 1, Thomas W Wakefield 1
PMCID: PMC3292052  NIHMSID: NIHMS354992  PMID: 22345593

Abstract

Deep vein thrombosis and pulmonary embolism are a significant health care concern, representing a major source of mortality and morbidity. In order to understand the pathophysiology of thrombogenesis and thrombus resolution, animal models are necessary. Mouse models of venous thrombosis contribute to our understanding of the initiation, propagation, and resolution of venous thrombus, as well as allow for the evaluation of new pharmaceutical approaches to prophylaxis and treatment of deep vein thrombosis. In this work we review the ferric chloride model, the inferior vena cava ligation model, the inferior vena cava stenosis models, and the electrolytic inferior vena cava model and compare their advantages and disadvantages.

Keywords: thrombosis, vascular biology, venous thrombosis, animal models, mouse


Venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism, are a major source of morbidity and mortality worldwide. Recent research estimates the incidence of venous thromboembolism in the United States alone at 900,000 per year, with a quarter of the cases resulting in fatality.1,2 In 2008, The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism, states “the disease disproportionately affects older Americans, and we can expect more suffering and more deaths in the future as the population ages—unless we do something about it.” This document invited multiple stakeholders, including all areas of research and the health care systems, to come together in a coordinated effort to reverse this dramatic projected trend.2 Animal models are fundamental to accomplishing this objective. Mouse models of DVT constitute a unique biological environment in which investigators may evaluate not only the biology behind DVT, but also new pharmaceutical approaches. Here we review the most widely used mouse models to evaluate venous thrombogenesis and thrombus resolution.

General Considerations

Impetus for Development of a Murine Model

Humans stand alone as the singular species with propensity to develop spontaneous DVT. Because Virchow’s original description of a canine model, there has been interest in the development of animal models of thrombosis to mimic the human condition.3 Initial labors were directed toward development of large mammal models.4,5 The transgenic mouse era led toward efforts to translate the existing models into the smaller rodent species. Mice are amenable for the study of venous thrombosis and have the advantages of relatively low cost and the availability of different genetically manipulated strains. However, important differences to humans include body size, life span, genetic differences, and vessel size. Nevertheless, mouse models have increased our understanding of venous thrombosis.

Applications in Mice

Studying the genetic defects in humans and mice is crucial in order to gain insight into venous thrombosis. A fairly complete list of genetic deficiencies involved in human bleeding disorders is known, but our knowledge regarding genetic factors related to the increased propensity toward thrombosis remains incomplete.6 Sequencing of the mouse genome has allowed physiological manipulation of gene addition (transgenic) and gene deletion (knockout) mice, which has greatly increased our understanding of thrombotic processes.7,8

Because, in most cases, it is not possible to obtain human samples from the site of DVT to study the disease, it is advantageous for researchers to use animal models to investigate DVT in a biological setting. The link between inflammation, innate immunity, and venous thrombosis has recently been demonstrated through impaired venous thrombus resolution via a non-MyD88 dependent toll-like receptor 9 pathway in mice undergoing venous ligation.9 Similarly, multiple aspects of inflammation and venous thrombosis have been derived from mouse models.10 The essential role of E-selectin in the pathogenicity of antiphospholipid antibody syndrome was directly demonstrated by a mechanical femoral vein injury in E-selectin knockout mice treated with antiphospholipid antibody syndrome antibodies.11 However, these observations still need to be confirmed in patients.

The understanding of the biological events associated with venous thrombosis and their manipulation by pharmacological agents is dependent on studying animal models. The relative successes of recombinant tissue plasminogen activator, enoxaparin, hirudin, and argatroban could not have been predicted without information gleaned from early preclinical laboratory experiments with animals, nor the failures of other anticoagulant drugs that appeared promising in in vitro studies but failed to live up to expectations.1216 The use of thrombosis models in rodents plays a crucial role in bridging the bench to bedside transition. For example, primate studies are validating mouse studies that have suggested P-selectin inhibitors are potential therapeutic agents in the prophylaxis and treatment of DVT.8,17,18

Acute Versus Chronic DVT in Mice

Mice have a short life span and high metabolic rate, compared to humans. Thus, events occur faster in mice. Clinically, DVT in humans can be defined as acute, subacute and chronic. In mice, acute DVT is defined, in terms of time, from thrombus induction up to 2 to 3 days. Beyond that time point, subacute DVT and chronic DVT occur. Neutrophil migration occurs during the acute phase, and they are the main inflammatory cells in both the vein wall and thrombus. A shifting between neutrophils and monocytes occurs by day 6. After that, monocytes become the predominant inflammatory cells in both vein wall and thrombus19 (Figure 1). In addition, fibrotic changes after DVT help us to understand stages of DVT in mice. Collagen deposition and tissue remodeling events, almost absent during acute DVT, are present during the more chronic stages in both vein wall and thrombus. Mouse models having long-term endpoints are suitable for the study of chronic DVT, with remodeling of the vein wall similar to what is observed in the post-thrombotic syndrome.4,20,21

Figure 1.

Figure 1

Schematic representation of stasis and flow models through acute venous thrombosis, sub-acute/chronic venous thrombosis, and chronic venous thrombosis.

Analytic Evaluative Methods

The mouse models presented in this review contribute to the understanding of the pathophysiology at various stages of DVT. Large vessel models (mostly involving the IVC) are used to explore both acute and chronic DVT.8,9,17,20,2225 These models can be used to measure various parameters, including thrombus formation, thrombus weights,8,9,17,20,2225 vein wall inflammatory cell counts,20 perform immunohistochemistry,20 and stain for fibrosis (Masson’s stain,9,20 Sirius Red stain). In addition, gene expression,20 protein levels (ELISA,20,23 western blot), and protein activity (eg, measuring matrix metalloproteinases using zymography)23 can be measured. In blood, microparticles, hematology, coagulation, and markers of inflammation (interleukin-6, CCL2, interleukin-1, soluble P- and E-selectin, etc.) can be studied.

Small Vein Models

Mechanical injury,26 endothelial stimulation,22,2730 and photochemical injury3137 are all important models to study venous thrombosis. For example, leukocyte and platelet rolling are studied in mesenteric venules stimulated with calcium ionophore A23187 using intravital microscopy.27,38 These studies analyze events that occur within the vein over a short period of time, helping to understand principles of thrombogenesis (acute thrombosis) but not long-term consequences of thrombosis. However they will not be reviewed in the current work because we are focusing on larger vein models.

Large Vein Models

Ferric Chloride Model

The ferric chloride model was initially developed over 20 years ago with the intent to study arterial thrombosis in a rat model.39 Ferric chloride induced thrombosis has been described in both microvascular28 and macrovascular models of mouse venous thrombosis.40 The mouse is anesthetized, the IVC is exposed through a midline incision, and the infrarenal surface cleared to the level of the iliolumbar veins. A 2-mm×4-mm filter paper is presoaked in 3.5% FeCl3 solution and placed on the surface of the vein for 2 to 3 minutes, then removed. Alternatively, microvascular thrombosis may be induced with the application of 10% FeCl3 to mesenteric venules or internal jugular vein.28,41 The resulting transmural vessel wall injury leads to the formation of occlusive thrombi.4 This model reliably produces thrombi within minutes post injury. The size and speed of thrombus formation is FeCl3 concentration/time of exposure dependent. In general, the resultant venous thrombus is smaller than those produced by stasis. A disadvantage of this model is the production of a transmural vein wall injury that mimics only a minority of clinical DVT cases (Table).

Table.

Mouse Models of Deep Vein Thrombosis

Model Ferric Chloride Model IVC Ligation or Stasis Model IVC Stenosis Model Electrolytic IVC Model
Brief method description A 2-×4-mm filter paper is pre-soaked in 3.5%–10% FeCl3 solution and placed on the surface of the venules, jugular or saphenous vein for 2–3 min. A nonreactive suture ligature is placed around the IVC just below the renal veins to produce complete blood stasis. A vein wall injury is induced with a vascular clip. Then, a 4-0 silk is tied around the IVC and onto a 5-0 Prolene. Then the Prolene is removed. A 7-0 Prolene is tied around the IVC and onto a 30 G needle. Then the needle is removed. This modification from the original model has been recently introduced. A needle placed within the IVC with electrical current forms a thrombus in constant presence of blood flow.
Branches Lateral branches are ligated and posterior branches cauterized. Branches remain open. Lateral branches are ligated and posterior branches remain open. Lateral branches are ligated and posterior branches remain open.
Advantages This model reliably produces occlusive thrombi within minutes postinjury and enables the study of vein thrombosis by simply measuring occlusion time. The IVC yields quantifiable amounts of vein wall tissue and thrombus. It has proven useful for evaluating interactions between the vein wall and the occlusive thrombus for assessing the progression from acute to chronic thrombosis. Reduced flow combined with temporary endothelial compression, produces a laminar thrombus allowing the study of cellular kinetics. This model has been widely used. Reduced flow produces a laminar thrombus allowing the study of cellular kinetics. Produces consistent thrombus size, enough sample quantity per mice to be able to study thrombogenesis, thrombus resolution and also new agents for DVT prophylaxis and treatment.
Disadvantages Produces a transmural vein wall injury that mimics a small population of clinical DVT. Lack of blood flow inhibits the maximal effect of administered systemic therapeutic agents on the thrombus and vein wall. The degree of stenosis is inconsistent leading to a constant variable in thrombus sizes. Some thrombus grows occluding the stenosis area and literally transforming the basis of this model into a stasis model. Poor suitability to study drugs. Requires 15 min for the electrolytic process. Possible vein wall injury at the site of the needle.
Model used mainly to study Acute vein thrombosis. Acute and chronic vein thrombosis mimicking the occlusive clinical scenario. Acute and chronic vein thrombosis mimicking the nonocclusive clinical scenario. Acute and chronic vein thrombosis mimicking the nonocclusive clinical scenario.
Variation in thrombus size End point is to study vein occlusion. No large variation. Large variation in thrombus size. No large variation.
References 30, 41, 42 9, 18, 21, 22, 26 27, 4547 25 48, 51, 52
Observation and recommendations The transmural damage is the initiation of some clinical cases of DVT (DVT posttrauma or burn injury). This model could be used on those particular scenarios. Compared to the other models, this particular model cannot reproduce the clinical scenario where a thrombus has reopened after DVT in patients, but it can mimic complete occlusion. Compared to the other models, these models can reproduce the clinical scenario where a thrombus has reopened after DVT in patients, but it cannot mimic complete occlusion observed in patients. Also, lacks reproducible thrombus size necessary for pharmaceutical studies. This model can reproduce the clinical scenario where a thrombus has reopened after DVT in patients, but it cannot mimic complete occlusion.

DVT indicates deep vein thrombosis; IVC, inferior vena cava.

IVC Ligation Model

This model provides a total stasis environment and results in the most severe vein wall reaction to thrombosis of the models discussed.8,17,20,23 Studies in rats suggest that after IVC ligation a combination of stasis-induced vein wall injury and enhanced tissue factor expression in endothelial cells and leukocytes produce thrombosis.42 In this model, mice are anesthetized and a midline laparotomy is performed. The small bowel is exteriorized and placed on a moistened gauze pad to the animal’s left. The infrarenal IVC is identified and all side branches are ligated with nonreactive 7-0 Prolene suture. Posterior venous branches are cauterized.23 A 7-0 Prolene suture is tied down on the IVC, caudal to the left renal vein. This model has been widely used by our group for the study of venous thrombosis.8,17,20,21 It provides reproducible thrombus weights beginning at 3 hours and extending to 21 days, for most mouse strains. It has proven valuable in the study of interactions between the vein wall and thrombus during the progression from acute to chronic inflammation and remodeling of the vein wall. Disadvantages include the lack of blood flow. A technical pitfall unique to this procedure is the potential to induce initial hypotension. However, compensation by vertebral veins is observed and the survival rate for this model is around 95%, based on our laboratory’s observations. In addition, the IVC cannot reopen because of the ligature. This model cannot reproduce the clinical scenario where a thrombus is nonocclusive, but it can mimic complete occlusion (Figure 2 and Table). As a guideline, data from our laboratories in C57BL/6 mice shows, approximate thrombus weights (IVC+thrombus at harvest), of 33 mg at day 2, 29 mg at day 6, and 18 mg at day 14.

Figure 2.

Figure 2

Schematic representation of ligation, stenosis and electrolytic inferior vena cava (IVC) models. 1 indicates renal veins; 2, infrarenal IVC; 3, iliac veins.

IVC Stenosis Model

This model was initially developed to study early acute thrombosis and results in a thrombus of similar morphology to the ligation model over time. Currently, the model is used to study acute and chronic DVT.24,43 In the original description of this model, a midline incision is performed and the small bowel exteriorized. No branches are ligated. A neurosurgical vascular clip is applied to the infrarenal IVC for 15 seconds twice, 30 seconds apart to damage the endothelium. A 5-0 Prolene is placed longitudinally along the ventral surface of the IVC and a 4-0 silk suture is tied around both the IVC and Prolene suture. The Prolene suture is then removed, allowing blood flow to resume.44 This model combines external compression with a reduction in blood flow to produce laminar thrombus at early time points and has been used to study thrombogenesis kinetics and the efficacy of therapeutic agents.44,45 A modification of this original technique was recently introduced where no external compression on the IVC is performed, lateral branches are ligated, posterior branches remain open, and a 7-0 Prolene is tied around the IVC and onto a 30 G needle. Then the needle is removed creating a ≈90% stenosis.22 Other investigators do not ligate the lateral branches. A significant disadvantage of this model is the large variation in the size of the thrombus with an absence of thrombi in some mice. In addition, the thrombus may lead to complete vessel occlusion. This model is most suited to analyzing the initiation of thrombosis (Table).

Electrolytic Vein Model

The electrolytic method is an alternative to the stenosis model.46 The use of electrolysis to generate venous thrombosis in a murine model was first described by Cooley et al utilizing the femoral vein and who recently characterized a new model of venous thrombosis.47,48 However, the small size of this vessel and thrombus limit the sample size for molecular analysis.46 The electrolytic IVC model (EIM) involves the identical anesthesia and operative approach as the ligation model. Venous side branches are ligated with 7 to 0 Prolene, but posterior branches remain open. A 25-gauge needle, attached to a 30-gauge silver-coated copper wire is inserted into the subcutaneous tissue (cathode) and caudal IVC (anode). A direct current of 25 μAmp is applied over 15 minutes generating free radicals, which results in endothelial cell activation. A small area of endothelial denudation was observed at the needle entry point, which can contribute to thrombus formation. A laminar thrombus is formed with maintenance of a flow channel. Thrombus weights remain consistent with acceptable standard deviations to detect differences in experimental groups with a sample size as small as 5 mice, from 6 hours to 14 days post injury.46,49,50 Importantly, the electrolysis does not affect the intravascular temperature.46,50 This model produces reliable and consistent thrombus weights over a wide range of endpoints, while also allowing for the study of anti-thrombotic and thrombolytic agents.46 Disadvantages include a longer operative time and damage to the vein wall at the needle insertion site. The EIM produces thrombi that do not occlude the IVC during acute and chronic DVT (unpublished data) because of the constant presence of flow, so it more closely resembles the clinical scenario where thrombus partially occludes a deep vein. As a guideline, data from our laboratories in C57BL/6 mice show an average thrombus weight (IVC+thrombus at harvest) of 15 mg at 2 days, 12 mg at 6 days, and 8 mg at 14 days.

Anatomic Vein Variations in Mice

The vein system in both human and mice varies enormously. The models that used the IVC to study thrombosis face the problem of what to do with the branches. Lateral and posterior branches are apparent in the area of the IVC where the thrombus forms. The flow dynamic within the IVC confers these branches an important role, potentially limiting the size of the thrombus in formation. In the IVC ligation model, the thrombus grows backwards, from cranial to caudal, from the ligature to the first open branch (lateral or posterior) and then stops growing. Thus, the importance of the lateral and posterior branches are critical and because there are mice with no lateral branches, the only alternative is to standardize the anatomy by ligating the branches that influence thrombus size. In the EIM model, the thrombus grows caudal to cranial, following the flow. The importance of the lateral branches is critical as in the ligation model but not the posterior branches likely because in the EIM the thrombus remains associated with the anterior wall of the IVC based on our laboratory’s observations. Thus, in the EIM, the ligation of the side branches is critical and the thrombus grows until the flow from the renal veins limit the thrombus extension.

Discussion

Animal models of venous thrombosis are necessary in order to understand the mechanisms of DVT and adequately test pharmaceuticals for treatment of this disease. As an example, we explored the concept that P-selectin inhibition would help to prevent or treat DVT. We conducted experiments using mice, rats, and currently baboons to test inhibitors of P-selectin.8,17,25,5154 Our findings suggest that blocking P-selectin limits thrombus formation and accentuates thrombus resolution, protecting the vein wall against fibrosis in all 3 species.8,17,25,5155

An ideal mouse model of DVT should be technically simple and fast to perform, easily reproducible, generate a large sample for molecular analysis, form thrombus within a deep vein, and provide consistent thrombus size. However, there is no ideal “DVT animal model” due to the simple reason that animals do not develop spontaneous DVT. Thus, investigators are forced to artificially trigger a thrombus within a vein. In this review we have given a detailed overview of the advantages and disadvantages of the large vein models of venous thrombosis. The ferric chloride model enables the study of vein thrombosis from experiments that can be obtained by simply measuring time to occlusion. The IVC ligation and stenosis models and the EIM allow the study of actual tissue samples from the area where vein thrombosis occurs (vein wall and thrombus) and also blood analysis (plasma, serum). In addition, all 3 models allow the investigation of acute and chronic DVT. The ligation model, in particular, is useful for studying those clinical scenarios where complete occlusion and no recanalization occurs causing a severe response in the vein wall. The flow models (stenosis and EIM) are useful to mimic nonocclusive clinical scenarios, either partial occlusion and/or recanalization.

Acknowledgments

The authors would like to thank Dr Katherine A. Shuster, DVM for reviewing this manuscript, and Diana Farris, Angela Hawley, and Nicole Ballard-Lipka for their technical expertise.

Sources of Funding

This study was supported by NIH grants HL070766, HL089407, HL076123, HL095091, HL092129, and HL083918.

Footnotes

Disclosures

None.

References

  • 1.Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: Recommendations from a national workshop. Am J Prev Med. 2010;38:S502–S509. doi: 10.1016/j.amepre.2010.01.010. [DOI] [PubMed] [Google Scholar]
  • 2.Wakefield TW, McLafferty RB, Lohr JM, Caprini JA, Gillespie DL, Passman MA. Call to action to prevent venous thromboembolism. J Vasc Surg. 2009;49:1620–1623. doi: 10.1016/j.jvs.2009.01.058. [DOI] [PubMed] [Google Scholar]
  • 3.Virchow R. Thrombosis and emboli. Canton, MA: Science History Publications; 1846. [Google Scholar]
  • 4.Jeske WP, Iqbal O, Fareed J, Kaiser B. A survey of venous thrombosis models. Methods Mol Med. 2004;93:221–237. doi: 10.1385/1-59259-658-4:221. [DOI] [PubMed] [Google Scholar]
  • 5.Didisheim P. Animal models useful in the study of thrombosis and antithrombotic agents. Prog Hemost Thromb. 1972;1:165–197. [PubMed] [Google Scholar]
  • 6.Ginsburg D. Identifying novel genetic determinants of hemostatic balance. J Thromb Haemost. 2005;3:1561–1568. doi: 10.1111/j.1538-7836.2005.01461.x. [DOI] [PubMed] [Google Scholar]
  • 7.Sands AT. The master mammal. Nat Biotechnol. 2003;21:31–32. doi: 10.1038/nbt0103-31. [DOI] [PubMed] [Google Scholar]
  • 8.Myers D, Jr, Farris D, Hawley A, Wrobleski S, Chapman A, Stoolman L, Knibbs R, Strieter R, Wakefield T. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J Surg Res. 2002;108:212–221. doi: 10.1006/jsre.2002.6552. [DOI] [PubMed] [Google Scholar]
  • 9.Henke PK, Mitsuya M, Luke CE, Elfline MA, Baldwin JF, Deatrick KB, Diaz JA, Sood V, Upchurch GR, Wakefield TW, Hogaboam C, Kunkel SL. Toll-like receptor 9 signaling is critical for early experimental deep vein thrombosis resolution. Arterioscler Thromb Vasc Biol. 2011;31:43–49. doi: 10.1161/ATVBAHA.110.216317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol. 2008;28:387–391. doi: 10.1161/ATVBAHA.108.162289. [DOI] [PubMed] [Google Scholar]
  • 11.Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost. 2003;1:843–848. doi: 10.1046/j.1538-7836.2003.00119.x. [DOI] [PubMed] [Google Scholar]
  • 12.Leadley RJ, Jr, Chi L, Rebello SS, Gagnon A. Contribution of in vivo models of thrombosis to the discovery and development of novel anti-thrombotic agents. J Pharmacol Toxicol Methods. 2000;43:101–116. doi: 10.1016/s1056-8719(00)00095-2. [DOI] [PubMed] [Google Scholar]
  • 13.Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature. 1981;291:590–591. doi: 10.1038/291590a0. [DOI] [PubMed] [Google Scholar]
  • 14.Leadley RJ, Jr, Kasiewski CJ, Bostwick JS, Bentley R, Dunwiddie CT, Perrone MH. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler Thromb Vasc Biol. 1998;18:908–914. doi: 10.1161/01.atv.18.6.908. [DOI] [PubMed] [Google Scholar]
  • 15.Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (cgp 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost. 1990;63:204–207. [PubMed] [Google Scholar]
  • 16.Fitzgerald DJ, Fitzgerald GA. Role of thrombin and thromboxane a2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1989;86:7585–7589. doi: 10.1073/pnas.86.19.7585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003;38:1075–1089. doi: 10.1016/s0741-5214(03)01033-4. [DOI] [PubMed] [Google Scholar]
  • 18.Ramacciotti E, Myers DD, Jr, Wrobleski SK, Deatrick KB, Londy FJ, Rectenwald JE, Henke PK, Schaub RG, Wakefield TW. P-selectin/PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. Thromb Res. 2010;125:e138–e142. doi: 10.1016/j.thromres.2009.10.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski SK, Burdick MD, Schmidt R, Kunkel SL, Greenfield LJ. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:258–268. doi: 10.1161/01.atv.15.2.258. [DOI] [PubMed] [Google Scholar]
  • 20.Wojcik BM, Wrobleski SK, Hawley AE, Wakefield TW, Myers DD, Jr, Diaz JA. Interleukin-6: A potential target for post-thrombotic syndrome. Ann Vasc Surg. 2011;25:229–239. doi: 10.1016/j.avsg.2010.09.003. [DOI] [PubMed] [Google Scholar]
  • 21.Henke PK, Varga A, De S, Deatrick CB, Eliason J, Arenberg DA, Sukheepod P, Thanaporn P, Kunkel SL, Upchurch GR, Jr, Wakefield TW. Deep vein thrombosis resolution is modulated by monocyte cxcr2-mediated activity in a mouse model. Arterioscler Thromb Vasc Biol. 2004;24:1130–1137. doi: 10.1161/01.ATV.0000129537.72553.73. [DOI] [PubMed] [Google Scholar]
  • 22.Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Kollnberger M, Wakefield TW, Lammle B, Massberg S, Wagner DD. Von willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117:1400–1407. doi: 10.1182/blood-2010-05-287623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Diaz JA, Ballard-Lipka NE, Farris DM, Hawley AE, Wrobleski SK, Myers DD, Henke PK, Lawrence DA, Wakefield TW. Impaired fibrinolytic system in apoe gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg. 2011 doi: 10.1016/j.jvs.2011.08.038. [epub ahead of print Nov. 23] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Humphries J, Gossage JA, Modarai B, Burnand KG, Sisson TH, Murdoch C, Smith A. Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis. J Vasc Surg. 2009;50:1127–1134. doi: 10.1016/j.jvs.2009.06.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Myers DD, Jr, Rectenwald JE, Bedard PW, Kaila N, Shaw GD, Schaub RG, Farris DM, Hawley AE, Wrobleski SK, Henke PK, Wakefield TW. Decreased venous thrombosis with an oral inhibitor of p selectin. J Vasc Surg. 2005;42:329–336. doi: 10.1016/j.jvs.2005.04.045. [DOI] [PubMed] [Google Scholar]
  • 26.Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus. 1994;3:247–251. doi: 10.1177/096120339400300408. [DOI] [PubMed] [Google Scholar]
  • 27.Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. Platelets adhere to and translocate on von willebrand factor presented by endothelium in stimulated veins. Blood. 2000;96:3322–3328. [PubMed] [Google Scholar]
  • 28.Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. Von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007;109:2424–2429. doi: 10.1182/blood-2006-06-028241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D, Wagner DD. Systemic antithrombotic effects of adamts13. J Exp Med. 2006;203:767–776. doi: 10.1084/jem.20051732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Bonnefoy A, Daenens K, Feys HB, De Vos R, Vandervoort P, Vermylen J, Lawler J, Hoylaerts MF. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial vwf from cleavage by adamts13. Blood. 2006;107:955–964. doi: 10.1182/blood-2004-12-4856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood. 2000;95:577–580. [PubMed] [Google Scholar]
  • 32.Day SM, Reeve JL, Myers DD, Fay WP. Murine thrombosis models. Thromb Haemost. 2004;92:486–494. [PubMed] [Google Scholar]
  • 33.Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 1998;97:1002–1008. doi: 10.1161/01.cir.97.10.1002. [DOI] [PubMed] [Google Scholar]
  • 34.Carmeliet P, Moons L, Stassen JM, De Mol M, Bouche A, van den Oord JJ, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol. 1997;150:761–776. [PMC free article] [PubMed] [Google Scholar]
  • 35.Rumbaut RE, Bellera RV, Randhawa JK, Shrimpton CN, Dasgupta SK, Dong JF, Burns AR. Endotoxin enhances microvascular thrombosis in mouse cremaster venules via a tlr4-dependent, neutrophil-independent mechanism. Am J Physiol Heart Circ Physiol. 2006;290:H1671–H1679. doi: 10.1152/ajpheart.00305.2005. [DOI] [PubMed] [Google Scholar]
  • 36.Rumbaut RE, Randhawa JK, Smith CW, Burns AR. Mouse cremaster venules are predisposed to light/dye-induced thrombosis independent of wall shear rate, cd18, icam-1, or p-selectin. Microcirculation. 2004;11:239–247. doi: 10.1080/10739680490425949. [DOI] [PubMed] [Google Scholar]
  • 37.Rumbaut RE, Slaff DW, Burns AR. Microvascular thrombosis models in venules and arterioles in vivo. Microcirculation. 2005;12:259–274. doi: 10.1080/10739680590925664. [DOI] [PubMed] [Google Scholar]
  • 38.Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: An interaction mediated by endothelial p-selectin. Proc Natl Acad Sci U S A. 1995;92:7450–7454. doi: 10.1073/pnas.92.16.7450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990;60:269–280. doi: 10.1016/0049-3848(90)90106-m. [DOI] [PubMed] [Google Scholar]
  • 40.Buyue Y, Whinna HC, Sheehan JP. The heparin-binding exosite of factor IXA is a critical regulator of plasma thrombin generation and venous thrombosis. Blood. 2008;112:3234–3241. doi: 10.1182/blood-2008-01-136820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Yang M, Kirley TL. Engineered human soluble calcium-activated nucleotidase inhibits coagulation in vitro and thrombosis in vivo. Thromb Res. 2008;122:541–548. doi: 10.1016/j.thromres.2007.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Zhou J, May L, Liao P, Gross PL, Weitz JI. Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. Arterioscler Thromb Vasc Biol. 2009;29:863–869. doi: 10.1161/ATVBAHA.109.185678. [DOI] [PubMed] [Google Scholar]
  • 43.Singh I, Burnand KG, Collins M, Luttun A, Collen D, Boelhouwer B, Smith A. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation. 2003;107:869–875. doi: 10.1161/01.cir.0000050149.22928.39. [DOI] [PubMed] [Google Scholar]
  • 44.Singh I, Smith A, Vanzieleghem B, Collen D, Burnand K, Saint-Remy JM, Jacquemin M. Antithrombotic effects of controlled inhibition of factor viii with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood. 2002;99:3235–3240. doi: 10.1182/blood.v99.9.3235. [DOI] [PubMed] [Google Scholar]
  • 45.Burnand KG, Gaffney PJ, McGuinness CL, Humphries J, Quarmby JW, Smith A. The role of the monocyte in the generation and dissolution of arterial and venous thrombi. Cardiovasc Surg. 1998;6:119–125. doi: 10.1016/s0967-2109(97)00162-2. [DOI] [PubMed] [Google Scholar]
  • 46.Diaz JA, Hawley AE, Alvarado CM, Berguer AM, Baker NK, Wrobleski SK, Wakefield TW, Lucchesi BR, Myers DD., Jr Thrombogenesis with continuous blood flow in the inferior vena cava: a novel mouse model. Thromb Haemost. 2010;104:366–375. doi: 10.1160/TH09-09-0672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Cooley BC, Szema L, Chen CY, Schwab JP, Schmeling G. A murine model of deep vein thrombosis: characterization and validation in transgenic mice. Thromb Haemost. 2005;94:498–503. doi: 10.1160/TH05-03-0170. [DOI] [PubMed] [Google Scholar]
  • 48.Cooley BC. In vivo fluorescence imaging of large-vessel thrombosis in mice. Arterioscler Thromb Vasc Biol. 2011;31:1351–1356. doi: 10.1161/ATVBAHA.111.225334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Alvarado CM, Diaz JA, Hawley AE, Wrobleski SK, Sigler RE, Myers DD., Jr Male mice have increased thrombotic potential: sex differences in a mouse model of venous thrombosis. Thromb Res. 2011;127:478–486. doi: 10.1016/j.thromres.2011.01.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Diaz JA, Wrobleski SK, Hawley AE, Lucchesi BR, Wakefield TW, Myers DD., Jr Electrolytic inferior vena cava model (EIM) of venous thrombosis. J Vis Exp. 2011;53:2737. doi: 10.3791/2737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Myers DD, Jr, Schaub R, Wrobleski SK, Londy FJ, III, Fex BA, Chapman AM, Greenfield LJ, Wakefield TW. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost. 2001;85:423–429. [PubMed] [Google Scholar]
  • 52.Meier TR, Myers DD, Jr, Wrobleski SK, Zajkowski PJ, Hawley AE, Bedard PW, Ballard NE, Londy FJ, Kaila N, Vlasuk GP, Schaub RG, Wakefield TW. Prophylactic p-selectin inhibition with psi-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost. 2008;99:343–351. doi: 10.1160/TH07-10-0608. [DOI] [PubMed] [Google Scholar]
  • 53.Myers DD, Jr, Wrobleski SK, Longo C, Bedard PW, Kaila N, Shaw GD, Londy FJ, Rohrer SE, Fex BA, Zajkowski PJ, Meier TR, Hawley AE, Farris DM, Ballard NE, Henke PK, Schaub RG, Wakefield TW. Resolution of venous thrombosis using a novel oral small-molecule inhibitor of p-selectin (psi-697) without anticoagulation. Thromb Haemost. 2007;97:400–407. [PubMed] [Google Scholar]
  • 54.Downing LJ, Wakefield TW, Strieter RM, Prince MR, Londy FJ, Fowlkes JB, Hulin MS, Kadell AM, Wilke CA, Brown SL, Wrobleski SK, Burdick MD, Anderson DC, Greenfield LJ. Anti-p–selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg. 1997;25:816–827. doi: 10.1016/s0741-5214(97)70211-8. discussion 828. [DOI] [PubMed] [Google Scholar]
  • 55.Myers DD, Jr, Henke PK, Bedard PW, Wrobleski SK, Kaila N, Shaw G, Meier TR, Hawley AE, Schaub RG, Wakefield TW. Treatment with an oral small molecule inhibitor of p selectin (psi-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg. 2006;44:625–632. doi: 10.1016/j.jvs.2006.05.021. [DOI] [PubMed] [Google Scholar]

RESOURCES